A real-time polymerase chain reaction (RT-PCR)-based screening assay has been developed to identify all the possible FGFR3-TACC3 variants in GBM tumor tissue, despite its structural heterogeneity at the genomic level and variability at the mRNA level [29]. Here, FGFR3 is linked to neoplasm.